Alnylam Announces Submission Of NDA In Japan For ONPATTRO - Quick Facts

Shutterstock photo

(RTTNews.com) - Alnylam Pharmaceuticals, Inc. ( ALNY ) announced it has submitted a New Drug Application (NDA) to Japan'sPharmaceuticals and Medical Devices Agency for approval of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. The company expects a decision from the MHLW and PMDA in mid-2019.

Patisiran has orphan drug designation from the Ministry of Health, Labor and Welfare, which makes it eligible for priority review as well as 10 years of market exclusivity, if approved. Patisiran is Alnylam's first drug submitted for regulatory review in Japan.

Read the original article on RTTNews (http://www.rttnews.com/2939187/alnylam-announces-submission-of-nda-in-japan-for-onpattro-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks
Referenced Symbols: ALNY

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?